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AbstrAct
Fluorescence-guided surgery (FGS) of cancer is an area of intense interest. 
However, FGS of cancer has not yet been shown to be curative due to residual 
microscopic disease. Human fibrosarcoma HT1080 expressing red fluorescent protein 
(RFP) was implanted orthotopically in the quadriceps femoris muscle of nude mice. 
The tumor-bearing mice were injected with high and low-dose telomerase-dependent, 
green fluorescent protein (GFP)-containing adenovirus OBP-401, which labeled the 
tumor with GFP. Fluorescence-guided surgery (FGS) or bright light surgery (BLS) 
was then performed. OBP-401 could label soft-tissue sarcoma (STS) with GFP in 
situ, concordant with RFP. OBP-401-based FGS resulted in superior resection of 
STS in the orthotopic model of soft-tissue sarcoma, compared to BLS. High-dose 
administration of OBP-401 enabled FGS without residual sarcoma cells or local or 
metastatic recurrence, due to its dual effect of cancer-cell labeling with GFP and 
killing. High-dose OBP-401 based-FGS improved disease free survival (p = 0.00049) 
as well as preserved muscle function compared with BLS. High-dose OBP-401-based 
FGS could cure STS, a presently incurable disease. Since the parent virus of OBP-401, 
OBP-301, has been previously proven safe in a Phase I clinical trial, it is expected 
the OBP-401-FGS technology described in the present report should be translatable 
to the clinic in the near future. 
IntroductIon 
Fluorescence-guided surgery (FGS) of cancer is an 
area of broad and intense interest [1]. In the clinic, sentinel 
lymph nodes have been labeled by the near-infrared (NIR) 
fluorescing dye indocyanine [2]. However, indocyanine 
does not specifically label tumor cells. 5-aminolevulinic 
acid (5-AA), a precursor of hemoglobin has been used 
to label malignant glioma with significant progression-
free survival benefit, but was not curative [3]. Folate 
conjugated to fluorescein isothiocyanate (FITC) was 
used for targeting folate receptor–α (FR-α) in ovarian 
cancer patients whereby deposits less than 1 mm could 
be resected but was not shown to be curative [4]. Urano et 
al. used fluorescence-guided laparoscopy to visualize and 
remove tumors illuminated by the probe, γGlu-HMRG. 
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invasive human ovarian cancer, which in a mouse model, 
expresses the probe-activating GTT enzyme, but cures 
were not demonstrated [5].
We previously reported the effectiveness of FGS 
to improve outcomes in retroperitoneal-implanted nude 
mouse model of human fibrosarcoma, expressing green 
fluorescent protein (GFP). Although tumor recurrence 
was reduced and disease-free survival (DFS) increased, 
the procedure was not curative [6].
In another study from our laboratory, after FGS 
of a human pancreatic cancer cell line expressing green 
fluorescent protein (GFP) in an orthotopic nude-mouse 
model, the surgical resection bed was irradiated with 
UVC. FGS-UVC-treated mice had increased DFS and 
overall survival (OS) compared to FGS-only treated mice; 
with DFS lasting at least 150 days, indicating the animals 
were cured. 
GFP has been used for labeling tumors in situ for 
FGS. Kishimoto et al. [7] selectively-labeled tumors with 
GFP using a telomerase-dependent adenovirus (OBP-401) 
that expresses the gfp gene only in cancer cells, which 
generally express the telomerase enzyme in contrast to 
normal cells. The labeled tumors could then be resected 
under fluorescence guidance. Tumors that recurred 
after FGS maintained GFP expression [8]. Because the 
recurrent cancer cells stably express GFP, detection of 
cancer recurrence and metastasis is also possible with 
OBP-401 GFP labeling, in contrast to fluorescent-antibody 
or other non-genetic labeling. Because tumors of all types 
express telomerase, the genetic labeling method that 
uses a telomerase-dependent adenovirus to deliver GFP 
specifically to tumors offers the potential of widespread 
application, since cancers of all types express telomerase. 
Approximately 11,000 soft tissue sarcomas (STS) 
are diagnosed every year in the United States [9-12]. 
The standard treatment of soft tissue sarcomas comprises 
wide resection with or without adjuvant radiotherapy and/
or chemotherapy. At 5 years, the cumulative probability 
of local recurrence reported in large series ranges from 
12% to 28% [13-17], and the cumulative probability 
of metastasis ranges from 21% to 40% [13-18]. Wide 
excision can include muscle, tendon, ligament, bone, and 
joints which often decease limb function. The presence 
or absence of residual cancer cells in the surgical area 
determines local recurrence and prognosis of survival. 
Local recurrence after adjuvant therapy is mostly resistant 
to treatment, resulting in poor prognosis [13-17].
We report here FGS in combination with OBP-
401 is curative, of an STS in an orthotopic model, with 
preservation of walking function.
results And dIscussIon 
GFP-expressing adenovirus obP-401 labels and 
kills sarcoma cells in vitro
Time-lapse imaging demonstrated that OBP-401 
labeled RFP-expressing HT1080 sarcoma cells with GFP 
(Figure 1A). OBP-401 labeled HT1080 cells with GFP in 
a dose-dependent manner (Figure 1B). GFP fluorescence, 
after OBP-401 infection of HT1080 cells, became stronger 
each day from day 2 to day 7 (Figure 1A). OBP-401 also 
killed HT1080 cells with GFP in a dose-dependent manner 
(Figure 1C). These data indicated that OBP-401 labeled 
sarcoma cells with GFP, and could subsequently kill them 
in vitro.
orthotopic sarcoma model
An orthotopic sarcoma model was developed with 
HT1080 RFP cells implanted in the quadriceps femoris 
muscles. The orthotopically-growing sarcoma cells 
invaded the quadriceps femoris muscles and femoral bone 
similar to the clinical course of STS. Tumor growth was 
visualized by RFP fluorescence.
bright-light surgery results in remaining sarcoma 
cells in the orthotopic model
We performed bright-light surgery (BLS) on the 
orthotopic sarcoma model (Figure 2A). Because the 
sarcoma invaded muscles and the femoral bone, the tumor 
margin was invisible under bright light. Extensive RFP-
expressing sarcoma cells remained after BLS (Figure 2A 
and 2D).
OBP-401-based fluorescence-guided surgery 
(obP-401-FGs) of orthotopic sarcoma
The orthotopic tumor growing in the quadriceps 
femur (100 mm3, diameter; 6 mm) was resected 3 days 
after i.t. injection of OBP-401 at 1×108 PFU (Figure 2A). 
OBP-401 conferred GFP fluorescence of the orthotopic 
sarcoma which was sufficiently bright to perform complete 
resection of the sarcoma (Figure 2C and 2D). Imaging 
showed that OBP-401 GFP labeling matched the tumor 
RFP fluorescence (Figure 2C). OBP-401-GFP-based FGS 
resulted in no detectable residual sarcoma cells (Figure 
2C and 2D).
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Figure 1: obP-401 labels soft tissue sarcoma cell line Ht1080-rFP with GFP and then kills them in vitro. HT1080 human 
fibrosarcoma cells expressing RFP cells are seeded in 6 well plates (1×105 cells well). OBP-401 was added at the indicated multiplicity 
of infection (MOI) 24 hours after cell seeding. Images were acquired with a FV1000 confocal laser scanning microscope (Olympus). A. 
Representative images of mock-infected HT1080 sarcoma cells (upper). Representative images of HT1080 sarcoma cells 2, 3, and 4 days 
after infection with OBP-401 at an MOI of 10 (middle). Representative images of HT1080 sarcoma cells 2, 3, and 4 days after infection 
with OBP-401 at an MOI of 30 (lower). Bar=500 μm. b. Histogram shows the frequency of GFP-expressing sarcoma cells at indicated 
days after infection of OBP-401. c. Histogram shows the surviving fraction of HT1080 sarcoma cells 6 days after infection of OBP-401 in 
vitro. Data are shown as average ± SD. N = 5.
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Figure 2: Comparison of OBP-401 based fluorescence-guided surgery with bright-light surgery for orthotopic soft 
tissue sarcoma. For the orthotopic sarcoma model, HT1080 cells (3×106) in Matrigel (BD) were inoculated in the left quadriceps femoris 
muscle of nude mice (5 weeks old). For fluorescence-guided surgery (FGS), OBP-401 was injected intaratumorally at 1×108 PFU when 
tumors reached approximately 100 mm3 (6 mm diameter). A. Representative whole-body images of mock-infected orthotopic sarcoma 
before and after bright-light surgery (BLS) (upper). Representative whole-body images of orthotopic sarcoma before injection of OBP-
401 and before and after OBP-401-based FGS (OBP-401-FGS) (lower). b. Representative high-magnification images of RFP-expressing 
orthotopic sarcoma tumor before and after BLS Bar=7.5 μm. c. Representative high-magnification images of OBP-401-GFP labeled, 
RFP-expressing orthotopic sarcoma before and after OBP-401-FGS. d. Bargraphs shows the comparison of fluorescent area between 
BLS-treated tumors and OBP-401-FGS-treated tumors (p = 0.001) (left). Fluorescent area is calculated with ImageJ software. Bargraphs 
shows the comparison of fluorescence intensity of BLS-treated tumors and OBP-401-FGS-treated tumors (p = 0.001) (right). Fluorescence 
intensity is calculated with ImageJ software. Data are shown as average ± SD. N = 10.
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obP-401-FGs detects and resects residual 
sarcoma cells in the orthotopic sts model after 
bls
OBP-401 was intratumorally injected 3 days before 
BLS in HT1080-RFP tumors growing in the quadriceps 
femoris muscle (Figure 3A). After BLS, both RFP and 
GFP fluorescence were detected in the surgical bed (Figure 
3B). OBP-401 enabled detection of the residual cancer 
cells at the single cell level (Figure 3B). After OBP-401-
FGS, there were no residual cancer cells (Figure 3B). 
OBP-401 delineated the precise margin between cancer 
and normal tissue and whether there were residual cancer 
cells at the single-cell level (Figure 3C).
obP-401 based FGs resulted in recurrence-free 
surgery
We compared the rate of local recurrence after OBP-
401-FGS with BLS alone. Fluorescence imaging showed 
that 8 of 10 mice that underwent BLS had RFP-expressing, 
small, hard nodules 3 days after surgery, indicating that 
these mice had local recurrences (Figure 5A and 5B). In 
contrast there was no local recurrence in eight mice which 
received OBP-401-FGS (Figure 5A-5C, Table 1A). These 
data demonstrated that tumor visualization at the single-
cell level by OBP-401 enabled complete resection and 
prevented local recurrence.
obP-401-FGs enables minimally invasive, 
function-preserving surgery for sarcoma
Next, we confirmed whether high-dose OBP-401 
(2×108 PFU) FGS enabled minimally invasive surgery of 
sarcoma for preservation of muscle compared with BLS 
or low-dose FGS (Figure 5A). We injected high-dose 
OBP-401 into tumors in the orthotopic sarcoma model. 
High-dose injection of OBP-401 significantly reduced the 
size of tumors and inhibited tibial invasion compared with 
control tumor or low-dose injection of OBP-401 (Figure 
4A and 4B). We minimally resected tumors without 
residual disease under FGS, after high-dose injection of 
OBP-401 (Figure 4C). Six of 8 mice lost muscle function 
after FGS with low-dose OBP-401. In contrast, all mice 
preserved muscle function after FGS with high-dose 
OBP-401 (Figure 4D). These data suggested that OBP-
401-based FGS enabled muscle function preservation for 
sarcoma.
Inhibition of lung metastasis after high-dose obP-
401 and FGs
Eight of 10 mice received BLS had large lung 
metastases observed at necropsy (Figure 6A-C). Three of 
9 mice which received low-dose OBP-401-FGS had small 
metastasis in the lung (Figure 6, Table 1B). In contrast, 
none of the 10 mice which received high-dose OBP-401-
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Figure 3: obP-401-FGs removes residual sarcoma cells after bls. HT1080-RFP cells (3×106) in Matrigel were inoculated 
in the left quadriceps femoris muscle of nude mice (5 weeks). OBP-401 was injected intaratumorally at 1×108 PFU when tumors reached 
approximately 100 mm3 (6 mm diameter). The OBP-401-labeled orthotopic tumor was resected under bright light, and then residual 
tumor was resected under fluorescence. A. Representative whole-leg images of orthotopic sarcoma before and after BLS and FGS. b. 
Representative whole-tumor images of orthotopic sarcoma before and after BLS and FGS. c. Representative images of resected tumor after 
BLS (left) are after OBP-401-FGS (right). 
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Figure 4: High-dose obP-401 enables function-preserving surgery for orthotopic soft tissue sarcoma. HT1080 cells 
(3×106) in Matrigel (BD) were inoculated in the left quadriceps femoris muscle of nude mice (5 weeks). OBP-401 was injected intratumorally 
when tumors reached approximately 100 mm3 (6 mm diameter). A. Representative whole tumor images of orthotopic sarcoma before and 
after administration of low-dose OBP-401 (1×108 PFU) and high-dose OBP-401 (at 3×108 PFU). b. Bargraph shows the fluorescent area of 
control tumor and low-dose or high-dose OBP-401-treated tumors. Fluorescent area is calculated with ImageJ software. Data are shown as 
average ± SD. N = 10. c. Representative images of surgical area after BLS and low-dose or high-dose OBP-401-FGS. Dotted areas show 
surgical area. Arrowheads show tibia. RFP-expression means residual tumor. d. Representative images of resected tumor after BLS and 
low-dose or high-dose OBP-401-FGS. e. Bargraph shows the volume of resected tumor with BLS and low-dose or high-dose OBP-401-
FGS (lower). Data are shown as average ± SD. N = 10, p < 0.05. F. Representative image of left leg inoculated with low-dose or high-dose 
OBP-401-FGS. G. Bargraph shows the Basso, Beattie and Bresnahan (BBB) score of leg-function after low-dose OBP-401-FGS and high-
dose OBP-401-FGS (right) (p = 0.0023). 
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Figure 5: obP-401-based FGs prevents local recurrence after surgery. A. Representative whole-body images of orthotopic 
sarcoma 30 days after BLS (upper), 70 days after low-dose OBP-401-FGS (middle), and 70 days after high-dose OBP-401-FGS (lower). b. 
Comparison of volume of recurrent tumors after BLS, low-dose OBP-401-FGS, or high-dose OBP-401-FGS. Fluorescent area and intensity 
are calculated with ImageJ software. Data are shown as average ± SD. N = 10. c. Kaplan-Meyer curves show the disease-free survival after 
BLS or low-dose or high-dose OBP-401-FGS (p < 0.001). 
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FGS had any lung metastasis (Figure 6, Table 1B). High-
dose OBP-401-FGS significantly prolonged the overall 
survival rate compared with BLS alone (Figure 6D). 
These data indicated that high-dose OBP-401-based FGS 
controlled local recurrence and distant metastasis, thereby 
prolonging the survival rate.
Labeling tumors with OBP-401 has none of the 
weaknesses of non-genetic labeling, particularly loss 
of label over time and limited expression of the marker 
used for labeling. OBP-401 may be a general method for 
labeling tumors that express telomerase, which are the vast 
majority, and could have broad application for FGS.
The results of the present study suggest that OBP-
401-based FGS has clinical potential. An appropriate 
starting point would be sarcoma which is often superficial 
and amenable to i.t. injection of OBP-401 as was done in 
the present study, thereby, reducing potential for systemic 
toxicity. Administration via the i.t. route enables the 
potential of simple fluorescence imaging of the tumor with 
portable equipment [19] even in the patient to determine 
optimal labeling time, as well as dose, before FGS. 
The present study used both low-dose (1×108 PFU) 
and high-dose (3×108 PFU) OBP-401. Clinical studies can 
start with low-dose OBP-401 and proceed to high-dose 
after safety is demonstrated. 
A Phase I clinical trial of i.t. injection of OBP-301, 
the parent of OBP-401, in patients with advanced solid 
tumors was well tolerated [20]. Subsequent clinical studies 
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Figure 6: obP-401-based FGs reduces distant metastasis after surgery. To evaluate distant metastasis after BLS or OBP-401-
FGS in the orthotopic sarcoma model, mice were sacrificed at the time indicated after surgery and the lungs were imaged. A. Representative 
images of whole lungs in posterior view and anterior view after BLS, after low-dose OBP-401-FGS (middle). Representative images of 
whole lung in posterior and anterior views after high-dose OBP-401-FGS Red fluorescence (arrow heads)indicates metastasis. Bar=5 mm. 
b. Comparison of number of metastasis in the lung, fluorescencet area and fluorescenceintensity after BLS, low-dose OBP-401-FGS, or 
high-dose OBP-401-FGS. Fluorescence intensity and fluorescence area are calculated with ImageJ software. c. Kaplan-Meyer curves show 
the overall survival after BLS, low-dose OBP-401-FGS or high-dose OBP-401-FGS.
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could evaluate systemic administration of OBP-401 to 
target existing metastasis. 
The tumor-targeting technology described in 
the present report can be used along with previously-
developed tumor-targeting strategies [21-28].
MAterIAls And MetHods
GFP-expressing telomerase-specific adenovirus
In OBP-401 the promoter element of the human 
telomerase reverse transcriptase (hTERT) gene drives the 
expression of E1A and E1B genes, linked to an internal 
ribosome entry site, for selective replication only in cancer 
cells. The GFP gene is driven by the CMV promoter 
inserted in OBP-401 [29].
cell line and cell culture
The human sarcoma cell line HT1080 expressing 
RFP (HT1080-RFP) [30] was maintained and cultured in 
DMEM medium with 10% fetal bovine serum (FBS) and 
5% penicillin/streptomycin.
In vitro or ex vivo imaging
Time-course images of OBP-401 labeled HT1080 
sarcoma were acquired with an FV1000 confocal laser-
scanning microscope (Olympus, Tokyo, Japan) [31]. For 
whole-body or whole-tumor imaging, the OV100 Small 
Animal Imaging System (Olympus), was used [32].
Animal experiments
Athymic (nu/nu) nude mice (AntiCancer, Inc., 
San Diego) were kept in a barrier facility under HEPA 
filtration. Mice were fed with an autoclaved laboratory 
rodent diet (Tecklad LM-485, Western Research Products). 
All animal studies were conducted in accordance with 
the principles and procedures outlined in the National 
Institutes of Health Guide for the Care and Use of 
Laboratory Animals under Assurance Number A3873–01.
orthotopic sarcoma model
RFP-expressing HT1080 cells (3 × 106) suspended in 
Matrigel (20 uL) were inoculated into the left quadriceps 
femoris muscle of 5 weeks old female athymic nude mice 
[33]. Tumor progression was monitored by noninvasive 
fluorescence imaging (OV100).
OBP-401 based fluorescence-guided surgery 
(obP-401-FGs)
All animal procedures were performed under 
anesthesia using s.c. administration of a ketamine mixture 
[10 μl ketamine HCl, 7.6 μl xylazine, 2.4 μl acepromazine 
maleate, and 10 μl PBS]. Orthotopic STS tumors labeled 
with GFP by OBP-401 were observed with noninvasive 
fluorescence imaging (OV100) before FGS was 
performed. After surgery, the presence of cancer cells was 
observed with the OV100. If there were residual cancer 
cells, an additional resection was performed.
statistical analysis
Data are shown as means ± SD. For comparison 
between two groups, significant differences were 
determined using the Student’s t-test. For comparison 
of more than two groups, statistical significance was 
determined with a one-way analysis of variance (ANOVA) 
followed by a Bonferroni multiple group comparison test. 
Pearson chi-square analysis was used to compare the rate 
of local recurrence between BLS and OBP-401-FGS. 
Statistical analysis for disease-free survival and over-all 
survival was performed using the Kaplan-Meier test along 
with log-rank test. Pearson chi-square analysis was used 
to evaluate the rate of local recurrence and lung metastasis 
between BLS and OBP-401-FGS and the extent of limb 
preservation between low-dose OBP-401-FGS and high-
dose OBP-401-FGS. P values of < 0.05 were considered 
significant. 
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